HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS ON NOVEMBER 1, 2022
10/18/2022 - 08:05 AM
PLYMOUTH MEETING, Pa. , Oct. 18, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report third quarter 2022 financial results on Tuesday, November 1, 2022 , before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on November 1, 2022 , at 8:30 a.m. ET to discuss the results.
To participate in the call, please dial (800) 225-9448 (domestic) or +1 (203) 518-9708 (international), and reference passcode HRMYQ322. It is recommended that you dial in at least 10 minutes prior to the call.
The live and replayed webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/ .
About Harmony Biosciences At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA , our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com .
Harmony Biosciences Investor Contact: Luis Sanay , CFA 445-235-8386lsanay@harmonybiosciences.com
Harmony Biosciences Media Contact: Nancy Leone 215-891-6046 nleone@harmonybiosciences.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-report-third-quarter-2022-financial-results-on-november-1-2022-301651322.html
SOURCE Harmony Biosciences
Harmony Biosciences Holdings Inc
HRMY Rankings
#4980 Ranked by Stock Gains
HRMY Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
About HRMY
patients are at the beginning, middle, and heart of all we do. harmony biosciences, llc, is a privately-owned biopharmaceutical company. the company was established in october 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. harmony biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.